

Corindus designs, manufactures and commercializes precision vascular robotic systems for use in minimally invasive procedures. The Company's disposable medical device business model is enabled by a simple and low-cost cassette. The Company's initial product, the CorPath® 200 system, is **the world's first** to precisely drive coronary guidewires and stent/balloon catheters during percutaneous coronary intervention (PCI) procedures performed in a cath lab. While Corindus is focused initially on PCIs, its **open-platform** technology and IP allow the Company to address all segments of the vascular market—including peripheral, carotid, neuro and other more complex cardiac interventions such as structural heart repair.

Currently, PCI procedures are performed in a cath lab using x-ray angiography imaging, which exposes physicians to significant occupational hazards—including (1) radiation exposure (cancer, cataracts), as well as (2) chronic orthopedic ailments (spine) and fatigue due to the required use of heavy lead-protection garments. Indeed, there are many published studies showing that the cath lab is a hazardous work environment. For the first time in a cath lab, the CorPath® 200 system significantly reduces radiation exposure, fatigue, and other occupational hazards by protecting physicians from radiation and allowing them to operate in an ergonomically correct position.

The CorPath® 200 control console (right) is located in the interventional cockpit at the foot of the patient's bed. It allows a physician to drive a disposable/single-use cassette, containing the PCI devices, at the patient's bedside—using touchscreen and joystick controls—to remotely deliver and manipulate the coronary guidewires and stent/balloon systems during the PCI procedure. The CorPath® 200 console is similar in cost and footprint to an intravascular ultrasound (IVUS) console found in many cath labs today.



Precise device manipulation is a key challenge in PCI procedures today. Via CorPath® 200's stability and precision-controlled movements, the system empowers interventional cardiologists to improve their accuracy and potentially improve clinical outcomes in PCI procedures. Currently, these procedures are performed manually and rely on the variable dexterity of a physician's hands while standing bedside in a hazardous and stressful environment. In a recent market study, physicians *self-reported* that as many as 20% of procedures require placement of a second stent due to inaccurate placement of the first stent.

"The initial commercial use of CorPath® 200 is designed to offer increased precision *and* standardization of PCI outcomes by reducing variability among cardiologist-operators," says David M. Handler, President and CEO of Corindus. "Future clinical applications of robotic catheter manipulation may include chronic total occlusion or bifurcation, peripheral vessel stenting, and heart valve placement."

Key Information

Headquarters	Corindus Vascular Robotics 11 Erie Drive Natick, MA 01760 Phone: (508) 653-3335
Website	www.corindus.com
Initial Focus	Interventional cardiology
Financing	Privately held
Investors	HealthCor® Partners, 20/20 HealthCare Partners
Employees	16
Technology Platform	CorPath® 200 Vascular Robotic System
Contact:	Tal Wenderow Ofc: (508) 653-3335, x205 Cell: (617) 447-7078

Management Team

- David M. Handler**
President and Chief Executive Officer
- Tal B. Wenderow**
Co-Founder; Executive Vice President,
Marketing & Business Development
- Eamonn Fahy**
Director of Finance
- Michail M. Pankratov, MD, PhD**
Vice President, Clinical & Regulatory Affairs

Board of Directors

- Hillel Bachrach**
20/20 HealthCare Partners
- Peter J. Fitzgerald, MD, PhD**
Stanford University Medical Center
- David M. Handler**
Corindus Vascular Robotics
- Jeffrey C. Lightcap**
HealthCor® Partners
- Michael Y. Mashaal, MD**
HealthCor® Partners
- Tal B. Wenderow**
Corindus Vascular Robotics

CorPath® 200 Robotic Vascular System Platform: New Standard for Precise PCI

DESIGNED FOR PATIENTS

Enhanced precision and control leads to improved outcomes

Designed to help physicians place stents more precisely, thus reducing the possibility of having to implant more than one stent • Procedure time is potentially reduced, thus lowering the radiation dose to patients.

DESIGNED FOR PHYSICIANS

Interventional cardiologists are not exposed to radiation

CorPath® 200 is designed to provide a safe, radiation-free zone in which doctors perform PCI • Also, physician is comfortably seated in CorPath® 200 cockpit, reducing back pain and fatigue resulting from standing in a heavy lead apron all day.

DESIGNED FOR HOSPITALS

Enhanced efficiency/reduced costs, growth for cath lab

CorPath® 200 is world's first robotic technology designed for coronary interventions in a cath lab • Hospitals with robotics improve awareness, boost hospital's image • Increased opportunities for patient referrals, recruitment of physicians.